Medicines lifecycle is critical to fostering patient access to innovative therapeutic solutions, and delivering better health outcomes for patients.

Latest resource

Main deliverables

Main deliverable

Sort by
Sort by

D1.1 Survey analysis report on stakeholder-specific preferences, needs and expectations

To understand the needs, expectations and preferences from the perspective of different stakeholders, Work Package 1 (WP1) co-created with other WPs an online survey. The survey received 372 English language responses and 169 responses from 13 other European languages during the June and July in 2018. In addition to the survey, between June and October 2018, four different face-to-face consultations were carried out to involve the following vulnerable/ underrepresented and specific stakeholder groups : people with dementia, children and young 3 persons and people with rare diseases, as well as Health Technology Assessment (HTA) bodies.

18 March, 2019

PARADIGM at a glance

Meet the PARADIGM Consortium and get to know some interesting facts about them. PARADIGM’s mission is to provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement (PE) and demonstrates the ‘return on the engagement’ for all players.

31 January, 2019

PARADIGM Newsletter – 6 months of impact in patient engagement

Why yet another newsletter? Well, it's about creating a community as much as it is about communicating. We want to continue to build the base of participants in co-creating solutions to make patient engagement a greater reality.

17 October, 2018

PARADIGM One-pager 2018

PARADIGM’s objective is to develop much needed patient engagement processes and tools for three key decision-making points of the medicines development lifecycle: Research priority setting, Design of clinical trials and Early dialogue with regulators and HTA bodies.

2 August, 2018

Evolution of the Patient Engagement Ecosystem

Medicines lifecycle is critical to fostering patient access to innovative therapeutic solutions, and delivering better health outcomes for patients.

21 June, 2018

PARADIGM – 1st Open Patient Engagement Forum 2018

Patients Active in Research and Dialogues for an Improved Generation of Medicines (PARADIGM) had its first Open Patient Engagement Forum on the 10th of April in Brussels co-organised by PARADIGM, PFMD and EUPATI. The forum had four workshops focusing on prioritisation of the PARADIGM survey topics, building the PARADIGM story, assessing the value of patient engagement and utilising the survey to identify key stakeholders and most suited methodologies for the project. Follow the link for a short report on the events of the day:

20 June, 2018

Communications and External Engagement Plan

The Communications and Engagement plan lays down the map for PARADIGM communications activities throughout the project. It sets the guidelines for upcoming communication events, on stakeholders to reach, on the key messaging and the tools to use to reach them.

31 May, 2018

PARADIGM’s digital assets

The success of PARADIGM is closely linked to the dissemination and adoption of the outcomes of the project. PARADIGM aims at ensuring an extensive outreach to a broad set of stakeholders within the medicines development community at large. In order to do that a set of digital assets were developed.

23 January, 2017

Report on the first open Patient Engagement Forum

The PARADIGM consortium led by European Patients’ Forum and EFPIA held its first forum on 10th of April 2018, which was co-organized by EUPATI (European Patients’ Academy on Therapeutic Innovation) and PFMD (Patient Focused Medicines Development).

31 May, 2018